Shares ofEpizyme (NASDAQ: EPZM)are skyrocketing after the company disclosed that it has won coveted fast-track status for tazemetostat in additional cancer indications. As of 1:51 p.m. EDT, the stock had gained 15.1%.
Last November, tazemetostat won fast-track status for use inrelapsed/refractory diffuse large B-cell lymphoma (DLBCL) with an EZH2-activating mutation. Today, management announced it's secured fast-track designation for tazemetostat inrelapsed or refractory follicular lymphoma, either wild type EZH2 or with EZH2 activating mutations.
Image source: Getty Images.
The company also said today that its presentation of data on tazemetostat in these indications has been selected for theopening plenary sessionat the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on June 14.
The fast-track designation provides the company with greater contact with the FDA regarding its data, trial design, and FDA submission for approval of tazemetostat. It may also allow the company to eventually score priority review, which reduces the FDA decision timeline from 10 months to six months.
Epizyme plans to hold a conference call to discuss updated tazemetostat results on the same day as its presentation at the industry conference, so investors will have a little waiting to do before learning the latest efficacy and safety data for this drug.
Previously, preliminary phase 2 results reported last year showed up to a60% disease control rate in DLBCL patients treated with tazemetostat. At the time, management also reported the disease control rate was 100% in three patients with follicular lymphoma.
News of the fast-track designation, and the presentation, suggests data remains strong, but investors will need to parse through the full trial results, including safety data, before determining the commercial opportunity that may lie ahead for Epizyme. This remains a high-risk, high-reward stock that all but the most risk-tolerant investors ought to watch from the sidelines.
10 stocks we like better than EpizymeWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Epizyme wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.